Yun-Hee Noh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yun-Hee Noh has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Ju-Han Lee
Department of Biochemistry, Konkuk University School of Medicine, Seoul 05029, Korea
3 shared publicationsMingli Jin
Gachon Institute of Pharmaceutical Sciences, College of Pharmacy, Gachon University, Incheon 21936, Korea
3 shared publicationsSang-Don Han
Department of Medical Education, Konkuk University School of Medicine, Seoul 05029, Korea
3 shared publicationsInja Lim
Department of Physiology, College of Medicine, Chung-Ang University, Seoul 06974, Korea
2 shared publicationsJun-Ho Lee
Department of Biochemistry, Konkuk University School of Medicine, Seoul 05029, Korea
2 shared publicationsSeonguk Kim
Department of Biochemistry, Konkuk University School of Medicine, Seoul, Republic of Korea
2 shared publications
Latest Publications
- Open Access
- 29 February 2020
- Published by Korean Society for Biochemistry and Molecular Biology - BMB Reports in BMB Reports
- Vol. 53 (2) , 100-105
Heterogeneity in Liver Histopathology Is Associated With GSK-3β Activity and Mitochondrial Dysfunction in End-Stage Diabetic Rats on Differential Diets
Jun-Ho Lee, Soo-Bong Choi, Dong-Jun Sung, Mingli Jin, Ju-Han Lee, Ji-Young Mun, Tae-Sook Hwang, Sang-Don Han, Young-Tae Ro, Sung-Young Kim, Jueng-Soo You, Inja Lim & Yun-Hee Noh. BMB Reports 2020;53:100-5. https://doi.org/10.5483/BMBRep.2020.53.2.114
- 29 February 2020
- Published by Korean Society for Biochemistry and Molecular Biology - BMB Reports in BMB Reports
- Vol. 53 (2) , 100-105
Open AccessHeterogeneity in Liver Histopathology Is Associated With GSK-3β Activity and Mitochondrial Dysfunction in End-Stage Diabetic Rats on Differential Diets
Jun-Ho Lee, Soo-Bong Choi, Dong-Jun Sung, Mingli Jin, Ju-Han Lee, Ji-Young Mun, Tae-Sook Hwang, Sang-Don Han, Young-Tae Ro, Sung-Young Kim, Jueng-Soo You, Inja Lim & Yun-Hee Noh. BMB Reports 2020;53:100-5. https://doi.org/10.5483/BMBRep.2020.53.2.114
- Open Access
- 28 April 2015
- Published by Wiley in Journal of Diabetes Research
- Vol. 2015, 1-12
Euglycemia in Diabetic Rats Leads to Reduced Liver Weight via Increased Autophagy and Apoptosis through Increased AMPK and Caspase-3 and Decreased mTOR Activities
Euglycemia is the ultimate goal in diabetes care to prevent complications. However, the benefits of euglycemia in type 2 diabetes are controversial because near-euglycemic subjects show higher mortality than moderately hyperglycemic subjects. We previously reported that euglycemic-diabetic rats on calorie-control lose a critical liver weight (LW) compared with hyperglycemic rats. Here, we elucidated the molecular mechanisms underlying the loss of LW in euglycemic-diabetic rats and identified a potential risk in achieving euglycemia by calorie-control. Sprague-Dawley diabetic rats generated by subtotal-pancreatectomy were fed a calorie-controlled diet for 7 weeks to achieve euglycemia using 19 kcal% (19R) or 6 kcal% (6R) protein-containing chow or fedad libitum(19AL). The diet in both R groups was isocaloric/kg body weight to the sham-operated group (19S). Compared with 19S and hyperglycemic 19AL, both euglycemic R groups showed lower LWs, increased autophagy, and increased AMPK and caspase-3 and decreased mTOR activities. Though degree of insulin deficiency was similar among the diabetic rats, Akt activity was lower, and PTEN activity was higher in both R groups than in 19AL whose signaling patterns were similar to 19S. In conclusion, euglycemia achieved by calorie-control is deleterious in insulin deficiency due to increased autophagy and apoptosis in the liver via AMPK and caspase-3 activation.
- 28 April 2015
- Published by Wiley in Journal of Diabetes Research
- Vol. 2015, 1-12
Open AccessEuglycemia in Diabetic Rats Leads to Reduced Liver Weight via Increased Autophagy and Apoptosis through Increased AMPK and Caspase-3 and Decreased mTOR Activities
Euglycemia is the ultimate goal in diabetes care to prevent complications. However, the benefits of euglycemia in type 2 diabetes are controversial because near-euglycemic subjects show higher mortality than moderately hyperglycemic subjects. We previously reported that euglycemic-diabetic rats on calorie-control lose a critical liver weight (LW) compared with hyperglycemic rats. Here, we elucidated the molecular mechanisms underlying the loss of LW in euglycemic-diabetic rats and identified a potential risk in achieving euglycemia by calorie-control. Sprague-Dawley diabetic rats generated by subtotal-pancreatectomy were fed a calorie-controlled diet for 7 weeks to achieve euglycemia using 19 kcal% (19R) or 6 kcal% (6R) protein-containing chow or fedad libitum(19AL). The diet in both R groups was isocaloric/kg body weight to the sham-operated group (19S). Compared with 19S and hyperglycemic 19AL, both euglycemic R groups showed lower LWs, increased autophagy, and increased AMPK and caspase-3 and decreased mTOR activities. Though degree of insulin deficiency was similar among the diabetic rats, Akt activity was lower, and PTEN activity was higher in both R groups than in 19AL whose signaling patterns were similar to 19S. In conclusion, euglycemia achieved by calorie-control is deleterious in insulin deficiency due to increased autophagy and apoptosis in the liver via AMPK and caspase-3 activation.
- Open Access
- 29 August 2014
- Published by Springer Nature in Experimental & Molecular Medicine
- Vol. 46 (8) , e111
Diet control to achieve euglycemia induces significant loss of heart and liver weight via increased autophagy compared with ad libitum diet in diabetic rats
Intensive glucose control increases the all-cause mortality in type 2 diabetes mellitus (T2DM); however, the underlying mechanisms remain unclear. We hypothesized that strict diet control to achieve euglycemia in diabetes damages major organs, increasing the mortality risk. To evaluate effects on major organs when euglycemia is obtained by diet control, we generated a model of end-stage T2DM in 13-week-old Sprague-Dawley rats by subtotal pancreatectomy, followed by ad libitum feeding for 5 weeks. We divided these rats into two groups and for the subsequent 6 weeks provided ad libitum feeding to half (AL, n=12) and a calorie-controlled diet to the other half (R, n=12). To avoid hypoglycemia, the degree of calorie restriction in the R group was isocaloric (g per kg body weight per day) compared with a sham-operated control group (C, n=12). During the 6-week diet control period, AL rats ate three times more than rats in the C or R groups, developing hyperglycemia with renal hyperplasia. R group achieved euglycemia but lost overall body weight significantly compared with the C or AL group (49 or 22%, respectively), heart weight (39 or 23%, respectively) and liver weight (50 or 46%, respectively). Autophagy levels in the heart and liver were the highest in the R group (PPP<0.01 in the liver). In conclusion, glycemic control achieved by diet control can prevent hyperglycemia-induced renal hyperplasia in diabetes but may be deleterious even at isocaloric rate when insulin is deficient because of significant loss of heart and liver mass via increased autophagy.
- 29 August 2014
- Published by Springer Nature in Experimental & Molecular Medicine
- Vol. 46 (8) , e111
Open AccessDiet control to achieve euglycemia induces significant loss of heart and liver weight via increased autophagy compared with ad libitum diet in diabetic rats
Intensive glucose control increases the all-cause mortality in type 2 diabetes mellitus (T2DM); however, the underlying mechanisms remain unclear. We hypothesized that strict diet control to achieve euglycemia in diabetes damages major organs, increasing the mortality risk. To evaluate effects on major organs when euglycemia is obtained by diet control, we generated a model of end-stage T2DM in 13-week-old Sprague-Dawley rats by subtotal pancreatectomy, followed by ad libitum feeding for 5 weeks. We divided these rats into two groups and for the subsequent 6 weeks provided ad libitum feeding to half (AL, n=12) and a calorie-controlled diet to the other half (R, n=12). To avoid hypoglycemia, the degree of calorie restriction in the R group was isocaloric (g per kg body weight per day) compared with a sham-operated control group (C, n=12). During the 6-week diet control period, AL rats ate three times more than rats in the C or R groups, developing hyperglycemia with renal hyperplasia. R group achieved euglycemia but lost overall body weight significantly compared with the C or AL group (49 or 22%, respectively), heart weight (39 or 23%, respectively) and liver weight (50 or 46%, respectively). Autophagy levels in the heart and liver were the highest in the R group (PPP<0.01 in the liver). In conclusion, glycemic control achieved by diet control can prevent hyperglycemia-induced renal hyperplasia in diabetes but may be deleterious even at isocaloric rate when insulin is deficient because of significant loss of heart and liver mass via increased autophagy.
- 16 April 2013
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 29 (6) , 473-482
Improvement of β‐cell function after achievement of optimal glycaemic control via long‐term continuous subcutaneous insulin infusion therapy in non‐newly diagnosed type 2 diabetic patients with suboptimal glycaemic control
Background: Achieving euglycaemia by continuous subcutaneous insulin infusion (CSII) therapy alone has been shown to restore β‐cell function in patients with newly diagnosed type 2 diabetes. However, the efficacy has not been evaluated in patients with non‐newly diagnosed type 2 diabetes and suboptimal glycaemic control.Methods: Of the 1220 patients with type 2 diabetes who began CSII therapy from March 2000 to March 2007, we retrospectively selected patients using the following inclusion criteria: glycosylated haemoglobin (HbA1c) ≥ 7.0%, diabetes duration ≥ 1 year before CSII therapy, and duration of CSII therapy ≥ 6 months. We evaluated sequential changes in HbA1c and serum C‐peptide levels measured at a 6‐ to 12‐month intervals during CSII therapy.Results: In the 521 subjects included in this study [median diabetes duration 10 years; interquartile range (IQR) 6.0–17.0; CSII therapy ≤30 months], median HbA1c decreased from 8.7% (IQR 7.7–10.0) at baseline to 6.3% (IQR 5.9–6.9) after 6 months of CSII therapy (p < 0.0001). During the subsequent 24 months, median HbA1c levels were maintained between 6.3% and 6.5% (p < 0.0001 for all time points vs baseline). At 12 months after CSII therapy, median C‐peptide levels began to increase compared with baseline (fasting level 23% increase, p < 0.0001; 2‐h postprandial level 26% increase, p = 0.022), and the increase was maintained at 30 months (fasting level 39%; 2‐h postprandial level 53%; p < 0.0001 for all vs baseline).Conclusions: β‐Cell function was significantly improved in patients with non‐newly diagnosed and suboptimally controlled type 2 diabetes after achieving and maintaining optimal glycaemic control with long‐term CSII therapy alone. Copyright © 2013 John Wiley & Sons, Ltd.
- 16 April 2013
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 29 (6) , 473-482
Improvement of β‐cell function after achievement of optimal glycaemic control via long‐term continuous subcutaneous insulin infusion therapy in non‐newly diagnosed type 2 diabetic patients with suboptimal glycaemic control
Background: Achieving euglycaemia by continuous subcutaneous insulin infusion (CSII) therapy alone has been shown to restore β‐cell function in patients with newly diagnosed type 2 diabetes. However, the efficacy has not been evaluated in patients with non‐newly diagnosed type 2 diabetes and suboptimal glycaemic control.Methods: Of the 1220 patients with type 2 diabetes who began CSII therapy from March 2000 to March 2007, we retrospectively selected patients using the following inclusion criteria: glycosylated haemoglobin (HbA1c) ≥ 7.0%, diabetes duration ≥ 1 year before CSII therapy, and duration of CSII therapy ≥ 6 months. We evaluated sequential changes in HbA1c and serum C‐peptide levels measured at a 6‐ to 12‐month intervals during CSII therapy.Results: In the 521 subjects included in this study [median diabetes duration 10 years; interquartile range (IQR) 6.0–17.0; CSII therapy ≤30 months], median HbA1c decreased from 8.7% (IQR 7.7–10.0) at baseline to 6.3% (IQR 5.9–6.9) after 6 months of CSII therapy (p < 0.0001). During the subsequent 24 months, median HbA1c levels were maintained between 6.3% and 6.5% (p < 0.0001 for all time points vs baseline). At 12 months after CSII therapy, median C‐peptide levels began to increase compared with baseline (fasting level 23% increase, p < 0.0001; 2‐h postprandial level 26% increase, p = 0.022), and the increase was maintained at 30 months (fasting level 39%; 2‐h postprandial level 53%; p < 0.0001 for all vs baseline).Conclusions: β‐Cell function was significantly improved in patients with non‐newly diagnosed and suboptimally controlled type 2 diabetes after achieving and maintaining optimal glycaemic control with long‐term CSII therapy alone. Copyright © 2013 John Wiley & Sons, Ltd.